Effects of Long Noncoding RNA H19 Polymorphisms on Urothelial Cell Carcinoma Development

Po-Jen Yang, Ming-Ju Hsieh, Tung-Wei Hung, Shian-Shiang Wang, Shiuan-Chih Chen, Meng-Chih Lee, Shun-Fa Yang and Ying-Erh Chou
Additional contact information
Po-Jen Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Ming-Ju Hsieh: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Tung-Wei Hung: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Shian-Shiang Wang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Shiuan-Chih Chen: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Meng-Chih Lee: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Shun-Fa Yang: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Ying-Erh Chou: Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan

IJERPH, 2019, vol. 16, issue 8, 1-10

Abstract: Urothelial cell carcinoma (UCC) is one of the major malignancies of the genitourinary tract, and it is induced by carcinogenic epidemiological risk factors. H19 is one of the most crucial long noncoding RNAs (lncRNAs) and is involved in various types of bladder cancer. In this study, we examined H19 single-nucleotide polymorphisms (SNPs) to investigate UCC susceptibility and clinicopathological characteristics. Using real-time polymerase chain reaction, we analyzed five SNPs of H19 in 431 UCC patients and 431 controls without cancer. The results showed that patients with UCC carrying the H19 rs217727 CT + TT and rs2107425 CT + TT genetic variants had a high risk of developing muscle invasive tumors (pT2–T4) ( p = 0.030; p = 0.025, respectively). With a median follow up of 39 months, CT+TT polymorphisms of rs2107425 were associated with worse disease-specific survival (adjusted hard ratio (AHR) = 2.043, 95% confidence interval (CI) = 1.029-4.059) in UCC patients aged older than 65 years. In conclusion, our results indicate that patients with UCC carrying the H19 rs217727 CT + TT and rs2107425 CT + TT genetic variants have a high risk of developing muscle invasive tumors. Thus, H19 polymorphisms may be applied as a marker or therapeutic target in UCC treatment.

Keywords: urothelial cell carcinoma; polymorphism; H19; lncRNA (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/8/1322/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/8/1322/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:8:p:1322-:d:222338

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().